Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Inmagene Signs $920 Million Agreement to Acquire Four Chi-Med Immunology Therapies

publication date: Jan 11, 2021

Shanghai's Inmagene in-licensed global rights to four novel pre-clinical immunological candidates from Hutchison China MediTech (Chi-Med) in a deal that has a potential value of $920 million. With funding from Inmagene, the two companies will work together to advance the molecules through IND submissions. Inmagene will be in charge of global clinical development. For each candidate, Inmagene will be responsible for up to $95 million in development milestones and $135 million in commercial payments, plus up to double-digit royalties. Founded in 2019, Inmagene has raised over $40 million. More details....

Stock Symbols: (NSDQ/AIM: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China